Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Technomark Life Sciences is a global investment group founded in 1987, headquartered in London. Initially established as a strategic planning consultancy for large pharmaceutical companies, Technomark has transitioned into a venture capital firm specializing in the life sciences sector. The organization focuses on providing turn-key solutions for clinical development programs, primarily in the United States and Europe.
Over the years, Technomark has evolved its investment model from a traditional fund structure to a co-development approach, sharing the costs and risks associated with clinical studies. This model allows Technomark to engage more deeply with its portfolio companies, enhancing the potential for successful outcomes. The firm has a long-standing presence in the life sciences investment space, with a notable history of successful exits and partnerships.
Technomark Life Sciences invests primarily in the therapeutics sector, which includes biologics, new chemical entities (NCEs), orphan drugs, and medical technology. The firm targets companies engaged in Phase I-IV clinical trials, making investments that span from seed to Series C stages. Its geographical focus encompasses the United Kingdom, the European Union, the United States, and Israel.
The investment strategy emphasizes a co-development model, where Technomark shares the costs and risks of clinical studies, typically covering 30-60% of the expenses. This approach not only mitigates financial risk but also allows Technomark to provide strategic guidance and support to its portfolio companies. The firm seeks to partner with innovative startups that are advancing therapeutics and medical technologies, enhancing their chances of success in the competitive life sciences market.
Technomark Life Sciences has a history of successful investments, particularly during its fund era from 2000 to 2009, where it made eight investments in drug delivery, medtech, and therapeutics, achieving strong returns on seven of those. Currently, it is a strategic lead investor in MAX BioPharma, participating in a $13 million Series A round to develop Oxy210, an oxysterol-based drug candidate for metabolic dysfunction-associated steatohepatitis (MASH).
When pitching to Technomark, include detailed information about your clinical development plans and how you intend to navigate the regulatory landscape. Highlight any existing partnerships with clinical research organizations, as this aligns with their co-development model.
In 2024, Technomark Life Sciences became the strategic lead investor in MAX BioPharma's $13 million Series A funding round. This investment aims to support the development of Oxy210, an oxysterol-based drug candidate targeting metabolic dysfunction-associated steatohepatitis (MASH). Technomark's participation includes involvement in the Phase 1a/1b first-in-human study, highlighting its commitment to advancing innovative therapeutics.
What are Technomark Life Sciences' investment criteria?
Technomark Life Sciences focuses on investing in the life sciences sector, particularly in therapeutics and medical technology. The firm targets companies involved in Phase I-IV clinical trials and invests across various stages, from seed to Series C.
How can startups apply or pitch to Technomark?
Startups interested in partnering with Technomark Life Sciences should prepare a detailed pitch that outlines their business model, clinical development plans, and potential market impact. A warm introduction through industry connections may enhance the chances of securing a meeting.
What makes Technomark Life Sciences different from other investors?
Technomark distinguishes itself through its co-development investment model, which shares the costs and risks of clinical studies. This hands-on approach allows for deeper engagement with portfolio companies, providing strategic guidance and support throughout the development process.
What is Technomark's geographic scope?
The firm operates globally, with a primary focus on the United Kingdom, the European Union, the United States, and Israel. Technomark has established partnerships with boutique clinical contract research organizations (CROs) worldwide.
What is the typical check size for investments?
While specific check sizes are not publicly disclosed, Technomark engages in investments across a range of stages, from seed funding to Series C, indicating a flexible approach to funding based on the needs of the portfolio company.
What kind of post-investment involvement can startups expect?
Technomark Life Sciences takes an active role in its portfolio companies, providing strategic guidance and support throughout the clinical development process. This includes sharing the costs and risks associated with clinical studies, which enhances the potential for successful outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.